EGFR is a hot target for cancer therapy with many currently FDA approved drugs, and can activate at least 4 major downstream signalling cascades including; RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. This evidence concerns the gene PRRT2 and cancer.